FDA approves therapy for GSDIa - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves therapy for GSDIa

The one-time gene therapy is intended to restore the deficient enzyme needed to release stored glucose during fasting.

  • By

  • Kathryn Wighton

  • August 20, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves therapy for GSDIa

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: FDA approves therapy for GSDIa
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPatients or participants described in the source article.
Care SettingClinical management of rare inherited metabolic disorders, including nutritional management.

Key Highlights

  • Serious adverse reactions reported across clinical studies include anaphylaxis and adrenal insufficiency.

Guideline-Based Recommendations

Diagnosis

    Management

    • Nutritional management with frequent meals, cornstarch supplementation, and avoidance of certain foods containing simple sugars.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with glycogen storage disease type Ia aged 8 years and older.

        Pariglasgene brecaparvovec-opnr is a one-time gene therapy aimed at delivering a functional glucose-6-phosphatase gene.

        Clinical Best Practices

        • Avoidance of foods containing simple sugars as part of nutritional management.
        • Continuous supplementation with cornstarch to prevent hypoglycemia.

        Related Resources & Content

        Original Source(s)

        FDA approves therapy for GSDIa

        • by Kathryn Wighton

        • August 20, 2026

        Related Content

        Redefining Fontan Care: The Socio-Economic Impact of SVHD on Families

        Survey results reveal the long-term socio-economic and psychological impacts of single ventricle congenital heart disease (SVHD) on families. See how cardiologists Deepti Bhat, MD, and Naim Duran, MD, contributors to this research, are using findings to transform Fontan Clinic care at Phoenix Children’s.

        • by

        • August 12, 2026

        • 6 min
        Three-dimensional reconstruction by a computer-assisted surgery system for pediatric hydronephrosis caused by accessory renal artery compression: a single-center retrospective observational comparative case series

        American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy

        This American Epilepsy Society (AES) practice guideline provides updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to <36 months.

        • by

        • August 14, 2026

        • 2 min